Division of Life Science, School of Life Sciences and Biotechnology, Korea University, Seoul.
Immunology. 2011 Sep;134(1):73-81. doi: 10.1111/j.1365-2567.2011.03468.x. Epub 2011 Jun 29.
Aminoacyl tRNA synthetase-interacting protein 1 (AIMP1) is a novel pleiotropic cytokine that was identified initially from Meth A-induced fibrosarcoma. It is expressed in the salivary glands, small intestine and large intestine, and is associated with the innate immune system. Previously, we demonstrated that AIMP1 might function as a regulator of innate immune responses by inducing the maturation and activation of bone-marrow-derived dendritic cells (BM-DCs). Toll-like receptors (TLRs) are major pathogen-recognition receptors that are constitutively expressed on DCs. In this study, we attempted to determine whether AIMP1 is capable of regulating the expression of TLRs, and also capable of affecting the TLR-mediated activation of DCs. Expression of TLR1, -2, -3 and -7 was highly induced by AIMP1 treatment in BM-DCs, whereas the expression of other TLRs was either down-regulated or remained unchanged. In particular, the expression of the TLR2 protein was up-regulated by AIMP1 in a time-dependent and dose-dependent manner, and was suppressed upon the addition of BAY11-7082, an inhibitor of nuclear factor-κB. AIMP1 was also shown to increase nuclear factor-κB binding activity. Importantly, AIMP1 enhanced the production of interleukin-6 and interleukin-12, and the expression of co-stimulatory molecules on BM-DCs when combined with lipoteichoic acid or Pam3Cys, two well-known TLR2 agonists. Collectively, these results demonstrate that the AIMP1 protein enhances TLR2-mediated immune responses via the up-regulation of TLR2 expression.
氨酰-tRNA 合成酶相互作用蛋白 1(AIMP1)是一种新型的多功能细胞因子,最初是从 Meth A 诱导的纤维肉瘤中鉴定出来的。它在唾液腺、小肠和大肠中表达,与先天免疫系统有关。以前,我们证明 AIMP1 可能通过诱导骨髓来源的树突状细胞(BM-DC)的成熟和激活而作为先天免疫反应的调节剂。Toll 样受体(TLR)是在 DC 上持续表达的主要病原体识别受体。在这项研究中,我们试图确定 AIMP1 是否能够调节 TLR 的表达,以及是否能够影响 TLR 介导的 DC 激活。AIMP1 处理可高度诱导 BM-DC 中 TLR1、-2、-3 和 -7 的表达,而其他 TLR 的表达则下调或保持不变。特别是,AIMP1 以时间和剂量依赖的方式上调 TLR2 蛋白的表达,并在添加核因子-κB 抑制剂 BAY11-7082 时受到抑制。AIMP1 还显示增加核因子-κB 结合活性。重要的是,AIMP1 增强了白细胞介素-6 和白细胞介素-12 的产生,以及与脂磷壁酸或 Pam3Cys 联合使用时 BM-DC 上共刺激分子的表达,这两种都是众所周知的 TLR2 激动剂。总之,这些结果表明 AIMP1 蛋白通过上调 TLR2 表达增强 TLR2 介导的免疫反应。